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Abstract 
Proteolytic processing of the amyloid precursor protein (APP) leads to amyloid-β (Aβ) 
peptides. So far, the mechanism of APP processing is insufficiently characterized at the 
molecular level. Whereas the knowledge of Aβ generation by several proteases has been 
expanded, the contribution of the Kunitz-type protease inhibitor domain (KPI) present in two 
major APP isoforms to the complex proteolytic processing of APP is poorly understood. In 
this study, we have identified KPI-containing APP as a very potent, slow-binding inhibitor for 
the membrane-bound proteolytic regulator of iron homeostasis matriptase-2 by forming stable 
complexes with its target protease in HEK cells. Inhibition and complex formation depend on 
the intact KPI domain. By inhibiting matriptase-2, KPI-containing APP is protected from 
matriptase-2-mediated proteolysis within the Aβ region, thus preventing the generation of N-
terminally truncated Aβ. 
Keywords: amyloid β; enzyme kinetics; iron homeostasis; Kunitz inhibitor; type II 
transmembrane serine protease. 
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Introduction 
Matriptase-2 (MT2; the corresponding gene name is TMPRSS6) was shown to be a critical 
proteolytic regulator controlling iron metabolism. This was evidenced by patients with 
mutations in TMPRSS6 suffering from iron-refractory iron deficiency anaemia (IRIDA) 
(Finberg et al., 2008) and by murine models with an anaemic and iron deficient phenotype 
(Du et al., 2008; Finberg et al., 2010; Folgueras et al., 2008). It has been demonstrated that 
matriptase-2 downregulates hepcidin expression via BMP/SMAD signaling, probably by 
cleaving the BMP co-receptor hemojuvelin which was shown in vitro (Maxson et al., 2010; 
Silvestri et al., 2008). Matriptase-2-mediated hemojuvelin cleavage in vivo is under 
investigation (Krijt et al., 2011). 
Matriptase-2 belongs to the type II transmembrane serine proteases (TTSPs) within the 
superfamily of trypsin-like serine proteases which was discovered in 2002 (Hooper et al., 
2001; Velasco et al., 2002). This protease comprises a short N-terminal cytoplasmic tail and a 
large extracellular domain, the latter is divided into the stem region with the SEA domain, 
two CUB domains and three LDL receptor class A domains, and the protease domain. 
Matriptase-2 shares high similarities to the close homologue matriptase, involved in 
epidermal differentiation, which is tightly regulated by its cognate Kunitz-type inhibitor 
hepatocyte growth factor activator inhibitor-1 (HAI-1) (Bugge et al., 2007; Lin et al., 1999; 
Miller and List, 2013). Recently, we have found matriptase-2 to be inhibited by Kunitz-type 
inhibitor hepatocyte growth factor activator inhibitor-2 (HAI-2) in a cell system co-expressing 
both proteins (Maurer et al., 2013). 
In this study, the amyloid precursor protein (APP) was identified as another candidate 
inhibitor for matriptase-2 in cell-free and cell-based assays. APP is an ubiquitously expressed 
type I transmembrane protein discovered in 1987 (Goldgaber et al., 1987) with a still 
unknown physiological function. It is one of the most studied proteins since it has been 
implicated in the pathogenesis of Alzheimer’s disease (AD) (LaFerla and Oddo, 2005; Zheng 
and Koo, 2011). One of the pathologic hallmarks of AD is the accumulation of insoluble, 
extracellular amyloid plaques in the brain which are mainly composed of Aβ peptides derived 
from APP processing (Selkoe 1991). In the amyloidogenic pathway, cleavage of APP by  
β-site APP-cleavage enzyme 1 (BACE1) generates a membrane-bound C-terminal fragment 
(CTFβ) which is subsequently cleaved by the γ-secretase complex generating neurotoxic Aβ 
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peptides (Sastre et al., 2001; Vassar et al., 1999). The generation of Aβ peptides is prevented 
by processing of APP via the non-amyloidogenic pathway in which the α-secretase cleaves 
within the Aβ domain producing an extracellular soluble form of APP (sAPPα) with 
neuroprotective properties (Sisodia 1992).  
Three major isoforms APP695, APP751 and APP770 are known. The latter two contain a 
Kunitz-type protease inhibitor domain (KPI) of 51 amino acids located in the middle of the 
ectodomain and are widely expressed in non-neuronal cells whereas APP695, lacking the KPI 
domain, is the predominant isoform found in brain. The amino acid sequence of APP770 is 
shown in Figure 1A. The KPI domain of APP was shown to inhibit serine proteases in vitro 
such as trypsin and chymotrypsin (Bhasin et al., 1991; Shimokawa et al., 1993; Van Nostrand 
et al., 1989; Van Nostrand et al., 1990), and factors XIa and IXa (Schmaier et al., 1995). 
In this study, the inhibitory potential of KPI-containing APP towards matriptase-2 was 
determined by kinetic analysis. Additionally, the impact of KPI-mediated matriptase-2 
inhibition on APP processing was characterized. Our results indicate that the KPI domain 
protects APP from being degraded by matriptase-2. Uninhibited matriptase-2 processes APP 
to generate N-terminally truncated Aβ(6-40) in cell culture experiments.  
Results 
APP inhibits matriptase-2 in a cell-based system 
Recently, we have found matriptase-2 to be inhibited by the Kunitz-type inhibitor HAI-2 in a 
cell system co-expressing both proteins (Maurer et al., 2013). In order to validate whether 
KPI-containing APP inhibits matriptase-2 we co-expressed APP770 in HEK cells stably 
transfected with matriptase-2. For this, a vector encoding matriptase-2 C-terminally fused to a 
Myc- and His-tag and a vector encoding isoform APP770 containing KPI N-terminally fused 
to a Strep-tag were used (Figure 1). Matriptase-2 activity was measured in membrane 
fractions as well as concentrated conditioned media derived from matriptase-2-transfected 
HEK cells with the peptide substrate Boc-QAR-para-nitroanilide (Figure 2A) as reported 
previously (Stirnberg et al., 2010). In contrast, HEK-mock and APP770 expressing cells did 
not display any measurable activity. Interestingly, matriptase-2 activity was drastically 
diminished after co-expressing APP770 and matriptase-2 indicating that APP770 bears the 
potential to inhibit matriptase-2 proteolytic activity in a cell-based system.  
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Inhibition of matriptase-2 by APP770 was also demonstrated by determining the activity of 
cell surface-associated matriptase-2 on intact HEK-MT2-Myc-His cells in the presence of 
recombinant soluble APP770 (sAPP770). For this, sAPP770 was purified from conditioned 
media of transfected HEK cells (Figure S1A). While HEK-mock cells did not show any 
activity, the used fluorogenic peptide substrate Boc-QAR-7-amido-4-methylcoumarin (AMC) 
was cleaved by HEK-MT2-Myc-His cells with a more moderate activity in the presence of 30 
nM sAPP770 (Figure 2B). By applying these two different methods for assaying matriptase-2 
activity, the Kunitz-type inhibitor APP770 has been newly identified as an inhibitor of 
matriptase-2. 
APP770 acts as a potent, slow-binding inhibitor for matriptase-2 
In a next step, we characterized the inhibitory potency of APP770 against matriptase-2. For 
this, purified recombinant sAPP770 was incubated with conditioned media derived from 
matriptase-2-expressing HEK cells in the presence of the fluorogenic substrate Boc-QAR-
AMC. Efficient shedding of active matriptase-2 allows the usage of concentrated media for 
enzyme kinetics (Dosa et al., 2012; Maurer et al., 2012; Sisay et al., 2010; Stirnberg et al., 
2010). The progress curves in the presence of different inhibitor concentrations were  
non-linear in the pre-equilibrium phase and approached linearity to achieve the binding 
equilibrium (Figure 2C) showing time dependent inhibition in the course of the assay. Hence, 
sAPP770 acts as a slow-binding inhibitor and the progress curves were analyzed by non-
linear regression using the slow-binding equation. The replot of kobs values versus inhibitor 
concentrations [sAPP770] was linear (Figure 2D; inset) and the on (kon = 5.0×10
-4 s-1 nM-1) 
and off (koff = 8.0×10
-4 s-1) rate constants for inhibitor association/dissociation were obtained. 
The inhibition constant Ki of 0.66 ± 0.02 nM was calculated from the steady state rates of the 
progress curves, which were plotted versus the inhibitor concentration (Figure 2D) to obtain 
the IC50 value, from which the Ki value was calculated. In summary, the kinetic analyses 
confirmed a reversible, slow-binding mode of interaction indicating that sAPP770 binds to the 
active site of matriptase-2 in a substrate-like manner as proposed for Kunitz-type inhibitors 
(Eigenbrot et al., 2010; Farady and Craik, 2010). The same analysis was performed with the 
purified isoform sAPP751 also containing KPI. This isoform exhibited a Ki value in exactly 
the same low nanomolecular range as sAPP770 (Figure S2A and B) whereas sAPP695 and 
sAPP770ΔKPI, both containing no KPI domain, did not inhibit matriptase-2 (Figure S2C and 
D). In conclusion, the two KPI-containing sAPP770 and sAPP751 have equal inhibitory 
Unauthenticated
Download Date | 5/24/16 1:03 PM
Inhibition of matriptase-2 by KPI-containing APP 
6 / 33 
potencies towards matriptase-2 while KPI-lacking sAPP695 and sAPP770ΔKPI were 
ineffective. 
Matriptase-2 forms complexes with APP770 
As Kunitz-type inhibitors are known to form stable, SDS-resistant complexes with their target 
proteases, formation of complexes was analyzed by western blotting in HEK cells transfected 
with matriptase-2 and APP770. Matriptase-2 was detected with a molecular weight of ca. 120 
kDa in membrane fractions derived from HEK cells expressing matriptase-2 by the use of the 
c-Myc antibody after separating the proteins under reducing and non-reducing conditions 
(Figure 3A and B; left panels; lanes 4 and 5). Matriptase-2 undergoes a complex  
auto-processing mechanism resulting in cell surface release of a two-chain form (Jiang et al., 
2014; Stirnberg et al., 2010). After its synthesis as a membrane-bound, inactive one-chain 
zymogen of ca. 120 kDa, matriptase-2 is shed into the surrounding medium as an activated 
two-chain form of about 55 kDa comprising the protease domain of ca. 30 kDa tethered via a 
conserved disulfide bond to a portion of the stem region (Stirnberg et al., 2010). For this 
reason, the 30 kDa protease domain was detectable in the conditioned media of matriptase-2-
expressing cells after separating the samples under reducing conditions (Figure 3A; right 
panel; lanes 8 and 9) whereas under non-reducing conditions the disulfide-linked two-chain 
form of matriptase-2 of ca. 55 kDa was visible (Figure 3B; right panel; lanes 8 and 9). 
Interestingly, after co-expressing APP770, two additional matriptase-2-specific signals 
occurred in the conditioned media of ca. 130 and 170 kDa (Figure 3B; right panel; lane 9, 
asterisks) indicating that matriptase-2 is bound to interaction partners that are presumably 
distinct shed forms of APP770.  
APP-specific signals were detected by the use of Strep-Tactin AP conjugate in membrane 
fractions and in conditioned media of APP770-transfected cells of ca. 120 kDa (Figure 3C and 
D; left and right panels; lanes 3, 5, 7 and 9). The presence of soluble APP in conditioned 
media indicated cell surface release of APP770 in our cell system generated by α-secretase 
(sAPPα). Notably, after separating proteins of conditioned media under non-reducing 
conditions, a further signal of ca. 170 kDa was visible after co-expressing matriptase-2 
(Figure 3D; right panel; lane 9, asterisk) again demonstrating that APP770 is bound to 
matriptase-2. Beside this, an additional band of ca. 95 kDa suggested that matriptase-2 is 
presumably able to cleave APP770. These results show that matriptase-2 and APP770 interact 
to form stable, SDS-resistant complexes. APP770 was confirmed as an interaction partner of 
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matriptase-2 by purification of c-Myc-tagged matriptase-2 via the affinity to Strep-tagged 
APP770 bound to immobilized Strep-Tactin (Figure 4). 
Matriptase-2 inhibition by APP770 depends on intact KPI 
We next analyzed whether the inhibitory potential of APP770 against matriptase-2 and/or 
formation of the matriptase-2/APP complex depends on KPI of APP770. For this purpose, 
different mutated variants of APP770 were co-expressed in matriptase-2-transfected cells in 
which the whole KPI (ΔKPI) was deleted or a specific arginine residue was mutated. The 
canonical active site of Kunitz-domain containing proteins was identified as Arg260 in case of 
Kunitz domain I of HAI-1 (Lin et al., 2008) that assigned the inhibitory specificity against 
trypsin-like serine proteases which are characterized to show a clear preference for arginine 
residues in P1 position. Therefore, the corresponding Arg301 in KPI of APP770 was mutated 
to Glu in R301E (Figure 1A). As expected, APP770 with mutated ΔKPI and R301E failed to 
inhibit matriptase-2 to a similar extent as wild type APP770 (Figure 5A). This is in line with 
the absence of an inhibitory potency of purified KPI-lacking sAPP695 or sAPP770ΔKPI 
towards matriptase-2 (Figure S2C and D). In sum, these results show that KPI and specifically 
the amino acid Arg301 are critical in determining the inhibitory potential of APP against 
matriptase-2.  
Formation of APP/matriptase-2 complexes depends on intact KPI 
Additionally, we analyzed whether the lack of inhibitory capacity of the APP770 mutants 
correlates with the inability to form stable complexes with matriptase-2. For this reason, 
protein samples were separated under non-reducing conditions prior to Western blotting to 
maintain protein/protein interactions. In conditioned media, the soluble wild type and mutated 
APP770 fragments of ca. 120 kDa appeared (Figure 5B; lanes 3, 5 and 7) indicating that the 
mutated APP770 variants were released from the cell surface. Again, co-expression of wild 
type APP770 with matriptase-2 revealed the 170 kDa-complex and the cleaved 95  
kDa-fragment beside the 120 kDa-fragment (Figure 5B; lane 4; 170 kDa-complex marked 
with an asterisk). Notably, the complex at 170 kDa was absent in the generated APP770 
mutants (Figure 5B; lanes 6 and 8). Moreover, co-expression of matriptase-2 with mutated 
APP770 completely abolished the 120 kDa-fragment and increased the signal of the cleaved 
95 kDa-fragment (Figure 5B; lanes 6 and 8). Expression of wild type and mutated APP770 at 
ca. 120 kDa was confirmed in membrane fractions (Figure 5C; lanes 3 to 8).  
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Using a c-Myc antibody, matriptase-2 was visible at 55 kDa in conditioned media of single 
transfected cells (Figure 5D; lane 2). In co-transfected cells matriptase-2-specific signals 
occurred at ca. 55, 130 and 170 kDa (Figure 5D; lane 4; 170 and 130 kDa-complexes marked 
with asterisks). After co-expressing the mutated APP770 variants, complexes at ca. 130 and 
170 kDa were missing (Figure 5D; lanes 6 and 8) reflecting the results obtained by APP 
detection. In membrane fractions, matriptase-2 was again visible at ca. 120 kDa (Figure 5E; 
lanes 2, 4, 6 and 8). These results indicate that the mutated variants of APP770 being affected 
in their KPI domain obviously failed to form complexes with matriptase-2 according to their 
impaired inhibitory potential against matriptase-2. 
Matriptase-2 generates truncated versions of APP 
Expression of matriptase-2 resulted in the secretion of an additional fragment of APP770 into 
the conditioned media that migrates below (~95 kDa) the secreted sAPPα fragment generated 
by α-secretase (~120 kDa) (Figure 3D; right panel; lane 9 and Figure 5B; lane 4). Thus, wild 
type APP770 did not serve merely as an inhibitor but also as a substrate of matriptase-2. Since 
the Strep-tag fused to the N-terminus was used for detection of APP (Figure 1B), matriptase-2 
is able to generate C-terminally truncated versions of soluble APP770 in this cell system. 
Furthermore, after diminishing the inhibitory potential of APP770 by expressing the mutated 
versions affected in KPI, the apparent molecular mass of secreted APP770 shifted from 120 
kDa to 95 kDa (Figure 5B; lanes 6 and 8). These results show that matriptase-2 cleaves APP 
efficiently in case it is not inhibited by the APP KPI domain. In summary, the KPI domain is 
likely to protect APP from being degraded by matriptase-2 in our cell system.  
In order to analyze if matriptase-2 is involved in the generation of Aβ peptides, two quenched 
fluorogenic peptide substrates, M2460 and M2465, derived from amino acids 667 to 676 of 
human APP770 wild type (M2460) and human APP770 Swedish mutant (M2465) 
representing the β-secretase cleavage site (Figure 6A) were tested for their susceptibility to be 
cleaved by matriptase-2. Both substrates were efficiently cleaved by matriptase-2 in 
conditioned media of HEK-MT2-Myc-His cells (Figure 6B). As mentioned above matriptase-
2 has a clear preference to cleave after positively charged amino acids. Thus, cleavage of 
M2460 can potentially occur after Lys670 and/or Arg676. However, cleavage of the substrate 
M2465, in which Lys670 is mutated to Asn, clearly indicated that Arg676 in P1 position was 
targeted by matriptase-2.  
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Arg676 lies within the Aβ peptide region close to the N-terminus at amino acid position 
5 (Figure 1A). Therefore, we analyzed the generation of secreted Aβ peptides in dependence 
on matriptase-2 expression using wild type APP770, APP770ΔKPI and double mutant 
APP770ΔKPI/R676E. The Aβ peptides were immunoprecipitated from conditioned media of 
transfected HEK cells with antibody 4G8 recognizing an epitope within amino acids 18-22 of 
Aβ (Figure 1A) prior to immunoblotting with this antibody. As shown in Figure 7A  
(lower panel, lanes 1, 3 and 5) Aβ was generated after expression of APP. Aβ was also 
produced in the presence of matriptase-2 (Figure 7A, lower panel, lane 2). However, after  
co-expression of matriptase-2 and APP770ΔKPI a shift to a smaller Aβ peptide variant was 
observed (Figure 7A, lower panel, lane 4) indicating that matriptase-2 cleaves APP within the 
Aβ domain. In accord with this result, a larger CTF was additionally present in membrane 
fractions of these cells (Figure 7A, middle panel, lane 4). Assuming that the shorter version of 
the CTFs was generated by the α-secretase cleavage (CTFα) the larger matriptase-2 generated 
version (CTFMT2) occurred by cleavage at Arg
676. This is further supported by the absence of 
the higher molecular weight CTFMT2 in APP770
ΔKPI/R676E and matriptase-2-expressing cells 
(Figure 7A, middle panel, lane 6). However, a shift to a smaller Aβ peptide was still 
observable in this sample although the putative matriptase-2 cleavage site Arg676 was mutated 
indicating that matriptase-2 can additionally cleave Aβ at another position. 
Because antibody 4G8 not only detects Aβ, but also the p3 peptide that is generated by the  
α-secretory processing and subsequent cleavage of the CTF by γ-secretase we have also used 
the N-terminal neoepitope-specific antibody 82E1 recognizing amino acids 1-5 of the Aβ 
peptide. Again, detection of Aβ was possible after transfection of APP (Figure 7B, lower 
panel, lanes 3 and 5) verifying the generation of Aβ in these cells. Interestingly, co-expression 
of APP770ΔKPI and matriptase-2 completely abolished the Aβ signal detectable by antibody 
82E1 (Figure 7B, lower panel, lane 6) although Aβ was present in this sample as shown by 
using antibody 4G8 (Figure 7A, lower panel, lane 4), thereby confirming that matriptase-2 
cleaves within the N-terminal region of Aβ. The absence of the signal after co-expressing 
matriptase-2 and the mutated variant APP770ΔKPI/R676E (Figure 7B, lower panel, lane 8) may 
result from the inability to detect the mutated neoepitope. Accordingly, the Aβ signal in lane 
7 could be derived from endogenously expressed APP which was also detectable as shown in 
lane 1 (Figure 7B, lower panel).  
Cleavage at Arg676 by matriptase-2 was further indicated by the absence of sAPPα in 
conditioned media of cells co-expressing matriptase-2 and the mutated variant APP770ΔKPI 
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using antibody 6E10 (Figure 7B, upper panel, lane 6). This antibody recognizes an epitope 
within amino acids 3-8 of the Aβ region. We postulated that after cleavage at Arg676, sAPPMT2 
was generated which escaped detection by antibody 6E10. The absence of the signal after  
co-expressing matriptase-2 and the mutated variant APP770ΔKPI/R676E (Figure 7B, upper panel, 
lane 8) may again result from the inability to detect the mutated epitope and the presence of 
the signal in lane 7 may be derived from Aβ generated from endogenously expressed wild 
type APP. 
To verify Aβ processing by matriptase-2 at position Arg676 in our cell-based system, mass 
spectrometric analyses were performed with samples derived from conditioned media of 
HEK-mock and HEK-MT2-Myc-His cells transfected with the mutated variant APP770ΔKPI 
after immunoprecipitation with antibody 4G8. These samples were already analyzed by 
western blotting resulting in a shift to a smaller Aβ peptide in the presence of matriptase-2 
(Figure 7A, lower panel, lanes 3 and 4). MALDI-TOF analyses revealed the presence of 
Aβ(1-40) derived from cells expressing APP770ΔKPI (Figure 8). Concurrently with the 
observed shift to a smaller Aβ peptide variant by western blottng, Aβ (6-40) was detectable by 
MALDI-TOF analyses instead of Aβ(1-40) after simultaneous expression of APP770ΔKPI and 
matriptase-2 undoubtedly confirming the cleavage site at position Arg676 targeted by 
matriptase-2. Additionally, Aβ(5-40) disappeared after co-expression of matriptase-2, 
possibly due to degradation to Aβ(6-40) by matriptase-2 (Figure 8). In HEK-mock cells  
Aβ(1-37/38) was detected (Figure 8, upper spectrum), presumably degraded to Aβ(6-37/38) in 
the presence of matriptase-2 (Figure S3). 
In a further experiment synthetic Aβ(1-42) was incubated with recombinant matriptase-2. As 
a control, synthetic Aβ(1-42) was incubated alone. While MALDI-TOF measurements 
revealed the presence of full length Aβ(1-42) in both samples (Figure S4) the application of 
LC-MS analysis identified Aβ peptides cleaved by matriptase-2. Indeed, Aβ(6-17) and  
Aβ(6-28) were found (Table 1) indicating that matriptase-2 cleaved at site Arg676.  
Discussion 
Whilst the proteases involved in APP processing have been studied intensively during the past 
years, the mechanism of controlling the activity of processing proteases due to the action of 
APP itself is largely unknown. APP exists in three major isoforms with unknown functions 
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from which two of them comprise a KPI domain bearing the potential to inhibit several serine 
proteases (Bhasin et al., 1991; Schmaier et al., 1995; Shimokawa et al., 1993; Van Nostrand 
et al., 1989, 1990). In our study, we have identified KPI-containing APP770 as a very potent 
inhibitor of the serine protease matriptase-2 by forming stable complexes depending on one 
critical arginine residue in APP, Arg301 in a transfected cell system. Due to its high inhibitory 
potential, KPI-containing APP770 is protected from being degraded by the overexpressed 
matriptase-2. Remarkably, APP770 did not inhibit the intrinsic activity of matriptase-2 
zymogen since the two processing events catalyzed by matriptase-2 itself, activation and 
shedding (Stirnberg et al., 2010), were detectable by the presence of a 30 kDa-fragment in 
conditioned media of matriptase-2 and APP770 expressing HEK cells (Figure 3A, lane 9). 
This could be due to a lower affinity of KPI-containing APP770 for the inactive zymogen 
than for the activated protease. 
Interestingly, in our cell system APP770 serves as an inhibitor and likewise as a substrate 
depending on the presence of the KPI domain. The deletion of the KPI domain changed the 
role of APP from being an inhibitor to being a substrate for matriptase-2. Matriptase-2 
hydrolyzes peptide bonds after basic amino acids with a clear preference for arginine over 
lysine in P1 position (Velasco et al., 2002). Accordingly, we could identify Arg676 
(corresponding to Aβ5) within the N-terminal region of the Aβ domain which is cleaved by 
matriptase-2 by MALDI-TOF analyses after co-expressing APP770ΔKPI and matriptase-2. 
Other sites, probably Lys687 (corresponding to Aβ16) which is the α-secretase cleavage site 
and Lys699 (corresponding to Aβ28), may also be targeted by matriptase-2 as shown by  
LC-MS analysis of a synthetic Aβ peptide after incubation with recombinant matriptase-2 
(Table 1) and by western blot analysis of Aβ after co-expressing APP770ΔKPI/R676E and 
matriptase-2 (Figure 7A, lower panel, lane 6). The shift to a smaller Aβ peptide variant in this 
sample indicated the presence of at least one additional cleavage site beside Arg676 that is 
presumably Lys699. Cleavage at this site would generate Aβ(1-28) with a similar molecular 
weight like Aβ(6-40). 
Additionally, matriptase-2 seems to target APP770 beside the Aβ domain. After  
co-expressing matriptase-2 and KPI-containing APP770, a smaller complex of 130 kDa 
appeared beside the 170 kDa-complex as observed by the use of the c-Myc-antibody  
(Figure 3B, lane 9). Because this smaller 130 kDa-complex could not be seen after detection 
of Strep-tagged APP770 (Figure 3D, lane 9), APP770 is presumably N-terminally truncated 
resulting in the loss of the Strep-tag.  
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A proposed model of matriptase-2 mediated processing of APP770 is shown in Figure 9. In 
our cell system, processing of KPI-containing APP770 can occur predominantly by  
α-secretase described as the non-amyloidogenic pathway producing sAPPα detectable in 
conditioned media and CTFα detectable in membrane fractions. The occurrence of these APP 
fragments, sAPPα and CTFα, is independent on matriptase-2 co-expression. Smaller amounts 
of APP770 can be processed by the amyloidogenic pathway since Aβ, presumably Aβ(1-40), 
was detectable in conditioned media. If APP is expressed without the KPI domain matriptase-
2 becomes active and catalyzes the cleavage after position Arg676. The cleavage may occur in 
full length APP generating sAPPMT2 and CTFMT2. The latter can be converted to Aβ(6-40) by 
the γ-secretase. Matriptase-2 cleavage may also occur in CTFβ liberating CTFMT2, in  
Aβ(1-40) liberating Aβ(6-40) and in sAPPα liberating sAPPMT2. As a consequence, in 
APP770ΔKPI and matriptase-2 co-expressing cells, sAPPMT2, CTFα, CTFMT2 and Aβ(6-40) 
were present in detectable levels.  
Taken together, we have demonstrated for the first time that the KPI domain determines the 
susceptibility of APP to proteolytic cleavage by the serine protease matriptase-2 in HEK cells. 
The proteolysis of APP by matriptase-2 generating, amongst others, N-terminally truncated 
Aβ peptides solely depends on the presence of KPI. Future experiments are necessary to 
analyze the biological relevance of matriptase-2-mediated APP processing. Additionally, it 
has to be elucidated whether KPI-containing APP is involved in iron homeostasis by 
regulating matriptase-2 activity. A link between APP and iron homeostasis was already 
suggested by describing an iron-responsive element in the 5`-untranslated region of the APP 
transcript (Rogers et al., 2002) and by reporting an interaction of APP and the iron exporter 
ferroportin (Wong et al., 2014). Recently, matriptase-2 was identified as a cell surface 
activator of metalloprotease meprin β thereby enhancing APP shedding (Jäckle et al., 2015). 
Materials and methods 
Cell lines and culture conditions 
Human embryonic kidney (HEK) 293 cells (Graham et al., 1977) were cultured in Dulbecco’s 
modified Eagle’s medium. Huh-7 cells were cultured in RPMI medium. Cells were cultured 
under a humidified atmosphere of 5% CO2 at 37°C. Both media were supplemented with 
penicillin (100 U/ml), streptomycin (100 µg/ml), and fetal bovine serum (FBS) (10%). 
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Additionally, Huh-7 cells were cultured in medium supplemented with glutamine (2 mM) and 
non-essential amino acids (0.1 mM; all substances and media from Life Technologies, 
Karlsruhe, Germany).  
Cloning 
The construction of the expression plasmids pcDNA4 and pcDNA4-MT2-Myc-His, and the 
generation of stably transfected HEK-MT2-Myc-His cells were described previously 
(Stirnberg et al., 2010). 
For the generation of all other plasmids total mRNA was isolated from Huh-7 cells with 
TRIZOL-Reagent (Life Technologies) and transcribed into cDNA using Omniscript RT kit 
(Qiagen, Hilden, Germany) and Oligo(dT) primer (Life Technologies) according to the 
instruction manuals. For the expression of APP770 (Leu18-Asn770) with a Strep-tag at the  
N-terminus, the whole APP open reading frame was amplified using primers 5’-GCT CCC 
GGT CTC TGC GCC CTG GAG GTA CCC ACT GAT GG-3’ and 5’-GCT CCC GGT 
CTC TGG CCC TAG TTC TGC ATC TGC TCA AAG-3’ (BsaI recognition sites in bold, 
APP cDNA underlined) digested with BsaI and ligated into the BsaI-digested expressing 
vector pEXPR-IBA44 (IBA, Göttingen, Germany) to generate pEXPR-Strep-APP770.  
This vector was used to generate pEXPR-Strep-APP770ΔKPI encoding APP770 without the 
KPI domain by splicing by overlapping extension PCR with primers 5’-GCT CCC GGT 
CTC TGC GCC CTG GAG GTA CCC ACT GAT GG-3’ and 5’-CTT TGG GAC ATG GCG 
CTG CCC ACC TCT CGA ACC ACC TCT T-3’ for the amplification of the APP-encoding 
cDNA upstream of the KPI-encoding sequence, and 5’-AAG AGG TGG TTC GAG AGG 
TGG GCA GCG CCA TGT CCC AAA G-3’ and 5’-GCT CCC GGT CTC TGG CCC TAG 
TTC TGC ATC TGC TCA AAG-3’ for the amplification of the cDNA downstream of the 
KPI-encoding sequence. The vector pEXPR-Strep-APP770 was also subjected to site directed 
mutagenesis with GeneArt Site-Directed Mutagenesis System (Life Technologies) according 
to the instruction manual using primers 5’-CGA GAC GGG GCC GTG CGA AGC AAT 
GAT CTC-3’ and 5’-GCA CGG CCC CGT CTC GGC TTG TTC AGA G-3’ to generate 
pEXPR-Strep-APP770R301E. The vector pEXPR-Strep-APP770ΔKPI was subjected to site 
directed mutagenesis using primers 5’-GGA TGC AGA ATT CGA ACA TGA CTC AGG 
ATA TG-3’ and 5`-CAT ATC CTG AGT CAT GTT CGA ATT CTG CAT CC-3’ to generate 
pEXPR-Strep-APP770ΔKPI/R676E.  
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Matriptase-2 activity assay of concentrated media and membrane fractions 
Proteolytic activity measurements were performed with 5 μg total protein from concentrated 
media or 20 μg total protein of membrane fractions from HEK-mock or HEK-MT2-Myc-His 
cells either alone or transiently transfected with pEXPR-Strep-APP770, pEXPR-Strep-
APP770ΔKPI or pEXPR-Strep-APP770R301E using 200 μM Boc-QAR-para-nitroanilide 
(Bachem, Bubendorf, Switzerland) as described previously (Stirnberg et al., 2010). 
Purification of sAPP770 
HEK cells were grown in 175 cm2-flasks. After transfection with 84 µg pEXPR-Strep-
APP770, cells were cultured for two days with Opti-MEM. sAPP770 was isolated from the 
concentrated conditioned medium by affinity chromatography using the Strep-Tactin 
Sepharose column (IBA) following the manufacturer`s instructions. Purity of isolated 
sAPP770 was confirmed by SDS-PAGE (Figure S1) and concentration was determined by 
Bradford assay (Roti-Nanoquant; Carl Roth, Karlsruhe, Germany). 
Matriptase-2 activity assay of intact cells 
For measuring matriptase-2 proteolytic activity of intact cells, HEK-MT2-Myc-His cells or 
HEK-mock cells were grown on the surface of a 96-well plate. For this purpose, the cells 
were incubated in 200 µl of Dulbecco’s modified Eagle’s (DMEM)-medium (Gibco Life 
Technologies) to a confluence of approximately 70% under a humidified atmosphere of 5% 
CO2 at 37°C. After removing DMEM, assay buffer (50 mM Tris-HCl, 150 mM NaCl, pH 8.0) 
and 30 nM of purified sAPP770 were added to each well. The reaction was started 
immediately by adding 0.8 µl of the fluorogenic peptide substrate Boc-QAR-AMC (10 mM 
stock solution). The final concentration of the substrate was 40 µM. The reaction was 
followed at 37°C for 50 min with an excitation wavelength of 340 nm and emission 
wavelength of 460 using the Fluostar Optima Plate Reader (BMG Labtech, Offenburg, 
Germany). 
Kinetics of matriptase-2 inhibition 
Inhibition assays of matriptase-2 in concentrated media of stably transfected HEK-MT2-Myc-
His cells in the presence of different concentrations of purified APP were performed by 
monitoring the release of 7-amino-4-methylcoumarin from the fluorogenic substrate  
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Boc-QAR-AMC using Fluostar Optima Plate Reader (BMG Labtech). Reactions were 
monitored with an excitation wavelength of 340 nm and emission wavelength of 460 nm over 
50 min at 37°C in a total volume of 200 µl assay buffer (50 mM Tris-HCl, 150 mM NaCl, pH 
8.0) in the presence of 40 µM substrate and different APP concentrations (2 to 10 nM).  
Progress curves of the reactions were analyzed by nonlinear regression using the slow-binding 
equation [P] = vs×t+(vi–vs)×(1–exp(–kobs×t))/kobs+d to give vs, vi and kobs, where [P] is the 
product concentration, vs is the final steady-state rate, vi is the initial rate, kobs is the observed 
first-order rate constant for the approach to steady-state, and d is the offset. To obtain IC50 
values for slow-binding inhibitors, vs values from reactions in the presence of the inhibitor 
and vs values obtained by linear regression of the uninhibited reaction in the time course 
between 2500 and 3000 s were used. This time course was chosen because of an observed 
curvature of the progress curves of the uninhibited reaction that did not result from substrate 
limitation. All kinetic measurements were carried out in duplicate with five different inhibitor 
concentrations. Mean vs values were plotted versus the inhibitor concentrations [I], according 
to vs = v0/(1+[I]/IC50) to obtain v0 and IC50 values, where v0 is the calculated rate of the 
reaction in the absence of the inhibitor. Standard errors (± SE) of these nonlinear regression 
analyses were determined. Ki values were calculated from equation Ki = IC50/(1+[S]/Km) with 
a Km value of 32.2 µM (Dosa et al., 2012). The obtained kobs values were replotted versus the 
inhibitor concentrations resulting in a linear correlation where kon' was given by the slope and 
koff by the ordinate-intercept. The kon value was calculated using the equation kon = kon' 
(1+[S]/Km). 
SDS-PAGE and immunoblotting 
Stably transfected HEK-mock or HEK-MT2-Myc-His cells grown in 25 cm2-flasks were 
transiently transfected with 12 µg pEXPR-Strep-APP770, pEXPR-Strep-APP770ΔKPI, 
pEXPR-Strep-APP770R301E or pEXPR-Strep-APP770ΔKPI/R676E by lipofection with 
LipofectamineTM 2000 (Life Technologies) in the presence of Opti-MEM (Life Technologies) 
according to the manufacturer’s instructions. Fourty-eight hours after transfection, culture 
supernatants were concentrated and membrane fractions and lysates were isolated as 
described previously (Stirnberg et al., 2010). An amount of 30 µg total protein from 
concentrated media, membranes or lysates were separated by SDS-PAGE (10% acrylamide) 
under non-reducing or reducing conditions and subjected to western blot analysis using 
monoclonal c-Myc antibody (clone 9E10; diluted 1:200) (Evan et al., 1985) or monoclonal 
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anti-APP antibodies (4G8, diluted 1:1000; 6E10, diluted 1:100; both from Covance, 
Princeton, New Jersey, USA) and alkaline-phosphatase-conjugated secondary antibody 
(diluted 1:10000; Novagen, Merck, Darmstadt, Germany). Strep-tagged APP was also 
detected by using Strep-Tactin alkaline phosphatase conjugate (IBA). Detection was 
performed with NBT/BCIP (Nitro Tetrazolium Blue chloride/5-bromo-4-chloro-3-indolyl 
phosphate; Sigma-Aldrich, Saint Louis, USA). Transfer of proteins onto nitrocellulose 
membranes was validated by Ponceau S staining. 
Co-purification of matriptase-2/APP complexes by affinity chromatography 
For detection of complexes formed by matriptase-2/APP770, 400 μg total protein of 
conditioned media derived from HEK-MT2-Myc-His or HEK-mock cells transiently 
transfected with pEXPR-Strep-APP770, were subjected to affinity chromatography using the 
Strep-Tactin Sepharose column (IBA) according to the manufacturer’s instructions. Elution 
fraction 3 was concentrated and subsequently analyzed by western blotting under reducing 
conditions using either the Strep-Tactin alkaline phosphatase conjugate for detection of 
APP770 or the c-Myc antibody for detection of matriptase-2. 
Kinetics of APP cleavage by matriptase-2 
To determine specific matriptase-2 cleavage sites within the APP amino acid sequence, two 
commercially available substrates covering the region from amino acids 667 to 676 harboring 
the β-secretase cleavage site were used (M2460, M2465; Bachem). Reactions were monitored 
with an excitation wavelength of 340 nm and emission wavelength of 460 nm over 20 min at 
37°C in a total volume of 200 µl in the presence of 40 µM substrate and conditioned media 
from matriptase-2-expressing HEK cells or of conditioned media from HEK-mock cells. 
Assay buffer was 50 mM Tris-HCl, 150 mM NaCl, pH 8.0. 
Detection of Aβ 
Secreted Aβ was detected with monoclonal antibodies 4G8 (epitope 18-22; Covance) and 
82E1 (neoepitope 1-5; IBL, Japan). While Aβ was directly detectable with antibody 82E1 
(diluted 1:1000) after separating 30 µg of total protein from concentrated culture supernatants 
of transfected HEK cells under reducing conditions by NuPAGE (Novex, Life Technologies, 
Carlsbad, USA) using MES running buffer, detection of Aβ with antibody 4G8 required an 
immunoprecipitation prior the immunoblotting. For this, culture supernatants were removed 
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20 hours after transfection and supplemented with 10 µg of antibody 4G8. After incubation 
for 12 hours at 4°C, magnetic beads conjugated with Protein G (New England Biolabs, 
Frankfurt am Main, Germany) were applied according to the manufactory’s instruction. Total 
protein of immunoprecipitation was separated by NuPAGE and subjected to Western blot 
analysis using antibody 4G8 (diluted 1:500). Horseradish peroxidase-conjugated secondary 
antibody was applied diluted 1:10 000. Chemiluminescence was detected using ECL 
advanced chemiluminescence kit (GE Healthcare Life Sciences, Freiburg, Germany). 
Mass spectrometric analyses 
Stably transfected HEK-mock or HEK-MT2-Myc-His cells grown in 25 cm2-flasks were 
transiently transfected with 12 µg pEXPR-Strep-APP770ΔKPI by lipofection with 
LipofectamineTM 2000 (Life Technologies) in the presence of Opti-MEM (Life Technologies) 
according to the manufacturer’s instructions. After 24 hours, Aβ was immunoprecipitated 
from conditioned medium with 4G8 antibody (epitope 18-22; Covance) and magnetic beads 
conjugated with Protein G (New England Biolabs, Frankfurt am Main, Germany). Protein G 
magnetic beads were washed twice in phosphate-buffered saline (PBS) and twice with 
ammonium acetate. Aβ was eluted twice with 300 µL of 50% acetic acid and vacuum dried. 
In an alternative experiment 1 µg synthetic Aβ(1-42) (H1368; Bachem) was incubated 
overnight at 37°C with 1 µg recombinant His-tagged matriptase-2 in a total volume of 10 µl. 
His-tagged matriptase-2 was purified as described previously (Figure S4A) (Jäckle et al., 
2015). 
The samples were subsequently analyzed by the Mass Spectrometry Unit, Institute of 
Biochemistry and Molecular Biology, University of Bonn. For MALDI-TOF measurements 
peptide solutions were desalted on Zip-Tip C18 (Merck Chemicals GmbH, Darmstadt, 
Germany), eluates dried in a vacuum concentrator and redissolved in 4 μl TFA 0.1 %. 1 μl 
was mixed with 1 μl matrix solution (ACN 50 %, TFA 0.1 %) on a ground steel target and 
analyzed in reflectron mode MALDI-TOF (autoflex III, Bruker Daltonik GmbH, Bremen, 
Germany). Data were processed and visualized with FlexAnalysis Software (Bruker 
Daltonik). 
For LC-MS analysis peptides were dissolved in 8 µl 0.1% trifluoroacetic acid. 1.5 µl were 
injected onto a C18 trap column (20 mm length, 100 µm inner diameter) coupled to a C18 
analytical column (200 mm length, 75 µm inner diameter), made in house with 1.9 µm 
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ReproSil-Pur 120 C18-AQ particles (Dr. Maisch, Ammerbuch, Germany). Solvent A was 
0.1% formic acid. Peptides were separated during a linear gradient from 4% to 40% solvent B 
(80% acetonitrile, 0.1% formic acid) within 80 min at a flow rate of 320 nl/min. The 
nanoHPLC was coupled online to an LTQ Orbitrap Velos mass spectrometer (Thermo Fisher 
Scientific, Bremen, Germany). Ions between 330 and 1600 m/z were scanned in the Orbitrap 
detector with a resolution of 30,000 (maximum fill time 400 ms, AGC target 106). The 25 
most intense precursor ions (threshold intensity 5000) were subjected to collision induced 
dissociation and fragments analyzed in the linear ion trap. Fragmented peptide ions were 
excluded from repeat analysis for 15 s. Raw data processing and analysis of database searches 
were performed with Proteome Discoverer software 2.0.0.802 (Thermo Fisher Scientific). 
Peptide identification was done with an in house Mascot server version 2.5.1 (Matrix Science 
Ltd, London, UK). Data were searched against human sequences from SwissProt (release 
2015_03). Precursor Ion m/z tolerance was 10 ppm, fragment ion tolerance 0.6 Da. Tryptic 
peptides were searched with up to two missed cleavages. Low scoring spectrum matches were 
searched again with semitryptic specificity with up to one missed cleavage. Oxidation (Met) 
and acetylation (protein N-terminus) were set as dynamic modifications. Mascot results from 
searches against SwissProt were sent to the percolator algorithm version 2.05 (Kall et al., 
2008) as implemented in Proteome Discoverer. Only proteins with two peptides (maximum 
posterior error probability 1%) were considered identified.  
Statistical analysis 
Statistical analysis was performed with standard statistical functions of GraphPad Prism using 
a two-tailed t test. If not stated otherwise, all values represent means ± SD. The error 
probability was set at p<0.05 (indicated in Figures by *), p<0.01 (**) or p<0.001 (***). 
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Tables and figures 
Table 1 Identified Aβ peptides by LC-MS analysis of samples shown in Figure S4. 
The single-letter amino acid code is used. 
 
Figure 1 Schematic illustration of the amino acid sequence and domain organization of 
human APP770.  
(A) The amino acid numbering of APP770 starts from the N-terminus with the signal peptide 
(SP) shown in light black. The Kunitz protease inhibitor domain (KPI) is highlighted in grey, 
the Aβ region numbered from 1-42 is highlighted in black and the transmembrane (TM) 
domain is underlined. The epitopes recognized by antibodies 4G8 and 6E10 are indicated. 
Position in Aβ Aβ Aβ + MT2 
1-16 [M].DAEFRHDSGYEVHHQK.[L] [M].DAEFRHDSGYEVHHQK.[L] 
4-16  [E].FRHDSGYEVHHQK.[L] 
6-17  [R].HDSGYEVHHQKL.[V] 
6-28  [R].HDSGYEVHHQKLVFFAEDVGSNK.[G] 
16-28 [Q].KLVFFAEDVGSNK.[G] [Q].KLVFFAEDVGSNK.[G] 
17-28  [K].LVFFAEDVGSNK.[G] 
17-29  [K].LVFFAEDVGSNKG.[A] 
18-28  [L].VFFAEDVGSNK.[G] 
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Amino acids mutated in this study are given in bold type (Arg301, Arg676). (B) The type I 
transmembrane protein APP770 was cloned as a fusion construct with an N-terminal Strep-tag 
(Strep-APP770), the type II transmembrane protein matriptase-2 was cloned as a fusion 
construct with a C-terminal Myc- and His-tag (MT2-Myc-His). After expression, all tags are 
exposed at the cell surface. Cat, serine protease catalytic domain; CUB, complement factor 
C1s/1r, urchin embryonic growth factor, BMP domain; L, low-density lipoprotein receptor 
class A domain; SEA, sea urchin sperm protein, enteropeptidase, agrin domain; TM, 
transmembrane domain. 
 
Figure 2 Inhibition of matriptase-2 proteolytic activity by APP770.  
(A) HEK-mock and HEK-MT2-Myc-His cells either alone or transiently transfected with 
pEXPR-Strep-APP770 were cultured for 2 days with Opti-MEM. Total protein from 
membrane fractions (20 μg; MF) or concentrated conditioned media (5 μg; CM) was 
incubated with 200 μM Boc-QAR-para-nitroanilide as a substrate. The release of  
para-nitroaniline was monitored at a wavelength of 405 nm for 20 min at 37°C. The resulting 
activities were normalized to proteolytic activity in concentrated media derived from  
HEK-MT2-Myc-His cells and measured in duplicate in at least two independent experiments. 
(B) Matriptase-2 activity was measured at the surface of intact HEK-MT2-Myc-His cells or 
HEK-mock cells grown on a 96-well plate. The reaction was started by adding 40 µM of the 
fluorogenic substrate Boc-QAR-AMC and 30 nM of purified sAPP770 and subsequently 
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followed at 37°C for 50 min. Data points for HEK-mock and HEK-MT2-Myc-His cells were 
shown previously (Beckmann et al., 2016). (C) Different amounts of purified sAPP770 were 
incubated with conditioned media derived from matriptase-2-expressing HEK cells in the 
presence of 40 µM of the fluorogenic substrate Boc-QAR-AMC. The release of 7-amino-4-
methylcoumarin from the fluorogenic substrate was monitored with an excitation wavelength 
of 340 nm and emission wavelength of 460 nm over 50 min at 37°C. (D) The progress curves 
were analyzed by nonlinear regression using the slow-binding equation. The final steady-state 
rates vs were plotted versus inhibitor concentrations to obtain an IC50 value which corresponds 
to Ki (1 + [S]/Km). Inset; The replot of kobs values versus inhibitor concentrations is linear and 
the on (kon = 5.0×10
-4 s-1 nM-1) and off (koff = 8.0×10
-4 s-1) rate constants for inhibitor 
association/dissociation were obtained.  
 
Figure 3 Stable complex formation of matriptase-2 and APP770.  
HEK-mock and HEK-MT2-Myc-His cells were left untreated or transiently transfected with 
pEXPR-Strep-APP770 and cultured for 2 days with Opti-MEM. Total protein (30 µg) of 
membrane fractions (left panels) or conditioned media (right panels) were separated under 
reducing conditions (A, C) or non-reducing conditions (B, D) prior immunoblotting. 
Matriptase-2 was detected using the monoclonal mouse anti-c-Myc antibody (A, B), APP was 
detected using the Strep-Tactin AP conjugate (C, D). Representative immunoblots from three 
independent experiments are shown. M, molecular mass markers; non-red., non-reducing; 
red., reducing. Formation of APP770/matriptase-2-complexes at 130 kDa and 170 kDa were 
marked with asterisks. 
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Figure 4 Co-purification of matriptase-2 and APP770 by affinity chromatography. 
Conditioned media (400 μg total protein) of HEK-MT2-Myc-His or HEK-mock cells either 
untreated or transiently transfected with pEXPR-Strep-APP770, were subjected to affinity 
chromatography using the Strep-tag purification technique. Elution fractions were analyzed 
by western blotting using either the anti-c-Myc antibody or the Strep-Tactin alkaline 
phosphatase conjugate. AP, affinity purification. 
 
Figure 5 Influence of KPI on the inhibitory potential of APP770 and formation of 
matriptase-2/APP770 complexes.  
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HEK-MT2-Myc-His cells either alone or transiently transfected with pEXPR-Strep-APP770, 
pEXPR-Strep-APP770R301E or pEXPR-Strep-APP770ΔKPI were cultured for 2 days with Opti-
MEM. (A) Total protein from membrane fractions (20 μg; MF) or concentrated conditioned 
media (5 μg; CM) was incubated with 200 μM Boc-QAR-para-nitroanilide as a substrate. The 
release of para-nitroaniline was monitored at a wavelength of 405 nm for 20 min at 37°C. 
The resulting activities were normalized to proteolytic activity in concentrated media derived 
from HEK-MT2-Myc-His cells and measured in duplicate in at least two independent 
experiments. (B)-(E) Total protein from conditioned media (30 µg; CM; B, D) was separated 
under non-reducing conditions, total protein from membrane fractions (30 µg; MF; C, E) was 
separated under reducing conditions prior to electroblotting and detection of APP with Strep-
Tactin AP conjugate (B, C) and matriptase-2 with the anti-c-Myc antibody as shown in (D, 
E). Lanes 1 and 9, molecular mass markers. Formation of APP770/matriptase-2-complexes at 
130 kDa and 170 kDa were marked with asterisks. 
 
Figure 6 Cleavage of APP peptides.  
(A) Equal amounts of proteins from conditioned media of HEK-mock or HEK-MT2-Myc-His 
cells were incubated with 40 µM of the quenched fluorogenic peptide substrates M2460 or 
M2465 for 20 min at 37°C. In these fluorescence-quenching substrates, the fluorescence of  
7-amino-4-methylcoumarin is quenched by Dnp (2,4-Dinitrophenyl). Upon cleavage, the 
fluorescence was recovered and monitored with an excitation wavelength of 340 nm and 
emission wavelength of 460 nm. (B) The amino acid sequence of M2460 represents the  
β-secretase cleavage site of wild type APP, the sequence of M2465 represents the β-secretase 
cleavage site of the Swedish mutant of APP.  
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Figure 7 Generation of truncated Aβ by matriptase-2.  
HEK-mock or HEK-MT2-Myc-His cells were left untreated or transfected with wild type 
APP770, APP770ΔKPI or APP770ΔKPI/R676E and cultured for 2 days with Opti-MEM. (A) After 
immunoprecipitation with antibody 4G8 (epitope within amino acids 18-22 of Aβ or 689-693 
of APP), secretion of Aβ was analyzed in conditioned media (CM). Total protein (30 µg) of 
lysates (Lys) and membrane fractions (MF) were analyzed as controls visualizing full length 
APP in lysates and C-terminal fragments (CTF) in membrane fractions using the same 
antibody. (B) Total protein (30 µg) of conditioned media (CM) was analyzed with antibodies 
6E10 (epitope within amino acids 3-8 of Aβ or 674-679 of APP) and 82E1 (neoepitope within 
amino acids 1-5 of Aβ) visualizing sAPPα and Aβ.  
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Figure 8 Proteomic identification of Aβ generated in HEK cells expressing APP770ΔKPI 
and matriptase-2. 
Stably transfected HEK-mock or HEK-MT2-Myc-His cells were transiently transfected with 
pEXPR-Strep-APP770ΔKPI. Aβ was immunoprecipitated from conditioned media with 4G8 
antibody (epitope 18-22) prior MALDI-TOF analyses. Upper spectrum: Aβ 
immunoprecipitated after expression of APP770ΔKPI in HEK-mock cells; lower spectrum: Aβ 
immunoprecipitated after expression of APP770ΔKPI in HEK-MT2-Myc-His cells. Range 
3600-4600 m/z. Peak detection of average m/z. Theoretical and observed masses for Aβ(1-40) 
are 4328.2/4328.5 m/z, for Aβ(6-40) 3709.9/3709.7 m/z, for Aβ(5-40) 3866.0/3865.5 m/z, for 
Aβ(1-37) 4073.0/4073.5 m/z and for Aβ(1-38) 4130.0/4129.3 m/z, respectively.  
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Figure 9 Processing of APP.  
APP can be processed either by α- or β-secretase producing extracellular soluble N-terminal 
fragments (sAPPα or sAPPβ) and membrane-bound C-terminal fragments (CTFα or CTFβ). 
Without the KPI domain APP can be additionally processed by matriptase-2 producing 
sAPPMT2 and CFTMT2. CTFs can be further degraded by the action of γ-secretase generating 
the small p3 fragment, Aβ(1-40) or Aβ(6-40). The recognition site for antibody 4G8 is 
indicated by a red cross mark. Cleavage sites for α-, β- and γ-secretases are indicated by a 
grey dash line, the cleavage site for matriptase-2 is indicated by a red line. All cleavage sites 
within full length APP are also indicated by amino acid numbers (numbering corresponds to 
Aβ peptide). 
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Supplementary figures 
 
Figure S1. Purification of recombinant sAPP770 and sAPP770ΔKPI.  
HEK cells transiently transfected with pEXPR-Strep-APP770 or pEXPR-Strep-APP770ΔKPI 
were cultured for 2 days with Opti-MEM. Conditioned medium was concentrated and 
subjected to Strep-Tactin affinity chromatography to isolate the soluble form of APP770 or 
APP770ΔKPI. Purity of isolated sAPP770 (A) and sAPP770ΔKPI (B) was confirmed by 
SDS-PAGE followed by Coomassie Brilliant Blue staining. Lane 1, flow-through; lane 2, 
wash fraction 1; lane 3, wash fraction 5; lanes 4-7, elution fractions; M, molecular mass 
markers. 
 
Figure S2. Inhibition of matriptase-2 by sAPP751, sAPP695 and sAPP770ΔKPI.  
The activity of matriptase-2 in concentrated media of stably transfected HEK-MT2-Myc-His 
cells in the presence of different concentrations of purified sAPP751 (A) and (B), sAPP695 
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(C) or sAPP770ΔKPI (D) was measured by monitoring the cleavage of the fluorogenic 
substrate Boc-QAR-AMC. Soluble APP751 and APP695 were purified as described 
previously (Jefferson, T., Causevic, M., auf dem Keller, U., Schilling, O., Isbert, S., Geyer, 
R., Maier, W., Tschickardt, S., Jumpertz, T., Weggen, S., Bond, J. S., Overall, C. M., Pietrzik, 
C. U., and Becker-Pauly, C. (2011) Metalloprotease meprin beta generates nontoxic  
N-terminal amyloid precursor protein fragments in vivo. J. Biol. Chem. 286, 27741-27750). 
(A) Different amounts of purified sAPP751 were incubated with conditioned media derived 
from matriptase-2-expressing HEK cells and the reaction was followed over 50 min at 37°C. 
(B) The progress curves were analyzed by nonlinear regression using the slow-binding 
equation. The final steady-state rates vs were plotted versus inhibitor concentrations to obtain 
an IC50 value which corresponds to Ki (1 + [S]/Km) of 2.1 ± 0.1 nM. Inset; The replot of 
kobs values versus inhibitor concentrations is linear and the on (kon = 4.5×10-4 s-1 nM-1) and 
off (koff = 4.7×10-4 s-1) rate constants for inhibitor association/dissociation were obtained. 
(C, D) Different amounts of purified sAPP695 (C) or sAPP770ΔKPI (D) were incubated with 
conditioned media derived from matriptase-2-expressing HEK cells and the reaction was 
followed over 50 min at 37°C. 
 
Figure S3. Proteomic identification of Aβ generated in HEK cells expressing 
APP770ΔKPI and matriptase-2.  
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Stably transfected HEK-mock or HEK-MT2-Myc-His cells were transiently transfected with 
pEXPR-Strep-APP770ΔKPI. Aβ was immunoprecipitated from conditioned media with 4G8 
antibody (epitope 18-22) prior MALDI-TOF analyses. Upper spectrum: Aβ 
immunoprecipitated after expression of APP770ΔKPI in HEK-mock cells; lower spectrum: 
Aβ immunoprecipitated after expression of APP770ΔKPI in HEK-MT2-Myc-His cells. Range 
3440-3560 m/z. Peak detection of average m/z. Theoretical and observed masses for Aβ(6-37) 
and Aβ(6-38) are 3454.7/3454.5 m/z and 3511.7/3510.6 m/z, respectively. 
 
Figure S4. Mass spectrometric analysis of synthetic Aβ.  
(A) Matriptase-2 was purified from the concentrated conditioned medium of stably 
transfected HEK-MT2-Myc-His cells by affinity chromatography using 250 mM imidazole 
and subsequently analyzed by western blotting using c-Myc antibody. (B) An amount of 1 μg 
synthetic Aβ(1-42) (H1368; Bachem) was incubated overnight at 37°C with ca. 1 μg 
recombinant His-tagged matriptase-2 in a total volume of 10 μl. The samples (upper 
spectrum: Aβ incubated with matriptase-2; lower spectrum: Aβ alone) were analyzed by 
MALDI-TOF by the Mass Spectrometry Unit, Institute of Biochemistry and Molecular 
Biology, University of Bonn. Range 740-5000 m/z. Peak detection of average m/z. 
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